NEW YORK, NY / ACCESS Newswire / June 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible violations of federal securities laws.
Novo Nordisk announced on June 23, 2025, that it would end its partnership with Hims & Hers Health, Inc. ("Hims") to distribute its weight loss drug Wegovy, claiming that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization' and are disseminating deceptive marketing that put patient safety at risk."
Following this news, Novo Nordisk stock fell over 5% on the same day. To obtain additional information, go to:
https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-2?prid=154924&wire=1&utm_campaign=32
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on ACCESS Newswire
